Recruiting
Endometrial cancer+12
RecruitingA study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.
InvestigationalNo placebo
A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.
InvestigationalNo placebo
- Disease:Endometrial cancerParaganglion neoplasm+11
- Substances:BelzutifanLenvatinib
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Belzutifan
- Sponsor:Merck Sharp & Dohme LLC



